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Abstract: Background: Uveal melanoma (UM) is the most common primary ocular malignancy in
adults in the Western world. UM with a mutation in SF3B1, a spliceosome gene, is characterized by
three or more structural changes of chromosome 1, 6, 8, 9, or 11. Also UM without a mutation in SF3B1
harbors similar chromosomal aberrations. Since, in addition to SF3B1, mutations in U2AF1 and SRSF2
have also been observed in hematological malignancies, UM without a SF3B1 mutation—but with the
characteristic chromosomal pattern—might harbor mutations in one of these genes. Methods: 42 UMs
were selected based on their chromosomal profile and wildtype SF3B1 status. Sanger sequencing
covering the U2AF1 (exon 2 and 7) hotspots and SRSF2 (exon 1 and 2) was performed on DNA
extracted from tumor tissue. Data of three UM with an SRSF2 mutation was extracted from the
The Cancer Genome Atlas (TCGA). Results: Heterozygous in-frame SRSF2 deletions affecting amino
acids 92–100 were detected in two UMs (5%) of 42 selected tumors and in three TGCA UM specimens.
Both the UM with an SRSF2 mutation from our cohort and the UM samples from the TCGA showed
more than four structural chromosomal aberrations including (partial) gain of chromosome 6 and 8,
although in two TCGA UMs monosomy 3 was observed. Conclusions: Whereas in myelodysplastic
syndrome predominantly missense SRSF2 mutations are described, the observed SRSF2 mutations
in UM are all in-frame deletions of 8–9 amino acids. This suggests that the R625 missense SF3B1
mutations and SRSF2 mutations in UM are different compared to the spliceosome gene mutations
in hematological cancers, and probably target a different, as yet unknown, set of genes involved in
uveal melanoma etiology.
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1. Introduction
Uveal melanoma (UM) is a primary malignant ocular tumor arising from melanocytes in the
uvea which consist of iris, ciliary body, and choroid. Symptoms are present in the majority of patients
with the most common presenting symptom being change in vision. Other presenting symptoms
include photopsia and floaters [1]. Metastatic disease with predominantly metastasis to the liver,
develops in almost half of all UM patients causing a poor prognosis [1,2]. Several prognostic factors
are described with mutations in BAP1, SF3B1, and EIF1AX, with or without loss of chromosome 3,
as important predictors of survival [3,4]. Tumors of uveal melanoma (UM) patients with somatic BAP1,
SF3B1, or EIF1AX mutations show a distinct chromosomal copy number variation (CNV) pattern.
Whereas EIF1AXmut tumors in general lack gross anomalies, BAP1mut tumors display monosomy
3 and isochromosome formation. SF3B1mut tumors are characterized by three or more structural
Cancers 2019, 11, 1200; doi:10.3390/cancers11081200 www.mdpi.com/journal/cancers
Cancers 2019, 11, 1200 2 of 8
variants, usually of chromosomes 1, 6, 8, 9, and 11 [5]. However, not all UMs with a typical SF3B1mut
CNV harbor a mutation in the SF3B1 component of the spliceosome complex. As in myelodysplastic
syndrome (MDS) and MDS-related diseases (such as chronic myelomonocytic leukemia and acute
myloid leukemia) in which mutations in other genes of the spliceosome complex such as SRSF2 and
U2AF1 are described [6–10], mutations in SRSF2 and other spliceosome factors are also observed in
UM [11]. Typical MDS-related mutations in SRSF2 involve codon 95 and are missense mutations
resulting in an amino acid change (in 74% of patients with an SRSF2 mutation) or in-frame deletions
starting at this codon (26%) [8]. Missense mutations in U2AF1 in MDS are almost exclusively described
in codon 34 (p.Ser34Phe and p.Ser34Tyr), 156 (Arg156His), or 157 (p.Gln157Arg and p.Gln157Pro) [7,12].
Therefore, mutation analysis of SRSF2 and U2AF1 covering these hotspots was performed on UM
tumors with no SF3B1 mutation but with an SF3B1-like chromosomal CNV pattern.
2. Results
Heterozygous in-frame deletions starting at codon 92 of SRSF2 were identified in two of the
selected 42 UM (p.(Tyr92_His99del); p.(Gly93_His100del)), (Figure 1). These mutations were mutually
exclusive for BAP1, SF3B1, and EIF1AX but harbored a GNAQ p.(Gln209Leu) mutation (Table 1).
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Figure 1. Single nucleotide polymorphism (SNP) array profile with the B-allele frequency from two
uveal melanoma samples with an SRSF2 mutation. On the x-axes the chromosomes are displayed.
(a) Uveal melanoma 1 (UM1). (b) Uveal melanoma 2 (UM2).
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Table 1. Overview of clinical characteristics, mutation status and copy number variation of uveal
melanoma (UM) patients with an SRSF2 mutation.
UM 1 UM 2
Clinical characteristics
Sex Female Male
Age at diagnosis (years) 63.0 57.3
Metastasis No No
Disease free survival (months) 76.8 128.8
Mutation status
SRSF2 Chr17(GRCh37):g.74732946_74732969delc.274_297del:p.(Tyr92_His99del)
Chr17(GRCh37):g.74732943_74732966del
c.277_300del:p.(Gly93_His100del)
U2AF1 Wildtype Wildtype
GNAQ Chr9(GRCh37):g.80409488T > Ac.626A > T:p.(Gln209Leu)
Chr9(GRCh37):g.80409488T > A
c.626A > T:p.(Gln209Leu)
GNA11 Wildtype Wildtype
SF3B1 Wildtype Wildtype
BAP1 Wildtype Wildtype
EIF1AX Wildtype Wildtype
Copy number variation
(Partial) gain of chromosome 6, 8, 21 2q, 6p, 8, 11, 17, 20q
(Partial) loss of chromosome 9p, 15 1p, 3, 4q, 12p
UM1 originates from the ciliary body and consists of mixed cell type with the presence of closed
vascular loops. Largest tumor diameter was 19 mm with a prominence of 8 mm. The other UM, UM2,
arose from the choroid and consist of spindle cells. No closed vascular loops were present and there
was no involvement of the ciliary body. The largest tumor diameter was 13 mm with a prominence of
5 mm with no extraocular extension.
Both UMs showed more than four chromosomal aberrations including gain of chromosome 6 and
8. The single nucleotide polymorphism (SNP) array profiles of these tumors are shown in Figure 2. Both
patients did not develop metastatic disease and have a disease-free survival of 76.8 and 128.8 months,
respectively. In none of the 42 samples a mutation in U2AF1 was detected.
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Figure 2. Mutations in the SRSF2 gene from two out of the 42 analyzed uveal melanoma patients.
(a) and (c) Uveal melanoma sample (UM1) with a p.Y92_H99del displayed in SeqPilot V4.3.0 (JSI
medical systems, Ettenheim, Germany) (a) and in SeqScape V3.0 (Thermo Fisher Scientific, Waltham,
MA, USA) (c). (b,d) Uveal melanoma (UM2) with a p.G93_H100del displayed in SeqPilot V4.3.0 (b)
and in SeqScape V3.0 (d).
Three previously described SRSF2 mutations were found in the data from the The Cancer Genome
Atlas (TCGA) database [11]. CNV analysis showed loss of chromosome 3 in two UMs and gain of
chromosome 8(q) in all three UMs. Gain of chromosome 1p was also present in two UMs and gain of
chromosome 6 in one sample. Two UMs have a p.(Gln209Leu) mutation in GNAQ and one harbors a
GNA11 mutation (p.(Gln209Leu)), (Table 2). No mutations in EIF1AX were detected, but one UM has
BAP1 mutation (c.518A > G:p.(Tyr173Cys)).
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Table 2. Overview of mutations in uveal melanoma samples with an SRSF2 or U2AF1 mutation. ROMS = Rotterdam Ocular Melanoma Studygroup; TCGA = The
Cancer Genome Atlas.
SRSF2 U2AF1 GNAQ GNA11 BAP1 EIF1AX
1. ROMS c.274_297del:p.(Tyr92_His99del) Wildtype c.626A > T:p.(Gln209Leu) Wildtype Wildtype Wildtype
2. ROMS c.277_300del:p.(Gly93_His100del) Wildtype c.626A > T:p.(Gln209Leu) Wildtype Wildtype Wildtype
3. TCGA c.274_297del:p.(Tyr92_His99del) Wildtype c.626A > T:p.(Gln209Leu) Wildtype Wildtype Wildtype
4. TCGA c.274_300del:p.(Tyr92_His100del) Wildtype Wildtype c.626A > T:p.(Gln209Leu) Wildtype Wildtype
5. TCGA c.519_536del:p.(Ser174_Ser179del) Wildtype Wildtype c.626A > T:p.(Gln209Leu) c.518A > G:p.(Tyr173Cys) Wildtype
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3. Discussion
In this study we identified deletions in SRSF2 in two UM harboring an SF3B1 specific SNP
array pattern albeit with no mutations of the SF3B1 hotspot regions. Studies have shown that in
myelodysplastic syndrome (MDS) SRSF2 was mutated in 12–14% of the cases and mutations in
U2AF1 occur in 15% of the MDS cases [7,8]. This is a higher frequency compared to UM, in which
SRSF2 mutations are detected in less than 5% of the specimens and no U2AF1 mutations have been
identified [11]. Three SRSF2 mutated UMs described in the literature are included in The Cancer
Genome Atlas (TCGA, https://cancergenome.nih.gov/). Two out of these harbor similar deletions
(Table 2) as we have identified in our cohort, and are mutually exclusive with BAP1 and EIF1AX,
similar to our own observations. The third SRSF2 mutation from TCGA is a deletion of amino acid
174–179 and co-exists with a BAP1 mutation. Surprisingly, this tumor showed a BAP1 specific CNV
profile, indicating that latter deletion of residues 174–179 has no or little pathogenic effect. However,
other spliceosome gene mutations can underlie UM pathogenesis but might not display the same
chromosomal anomalies as described in SF3B1 [5]. Furthermore, the low incidence of SRSF2 mutations
in UM suggests that other genes of the splicing machinery, such as U2AF35 or ZRSR2, might be mutated.
Mutations in other splicing genes than SF3B1 could be less frequently involved in the development of
UM compared to MDS in which mutations in several splicing genes have been identified [6,9,10].
Since Sanger sequencing was used for mutation analysis, we have focused on the hotspot regions
of U2AF1 and SRSF2 that are described in UM and other diseases. More extensive research about
mutations in all coding regions of these genes could increase the incidence.
Compared to SRSF2 mutations in MDS in which the vast majority are missense mutations [8],
we observed a preference for in-frame deletions in UM. Also, for SF3B1 in UM residue R625 is most
commonly mutated residue, whereas in other tumors predominantly the K700 residue of SF3B1 is
affected [6,11]. Thus, although the same gene is involved, mutations occur on different residues in
distinct diseases. Furthermore, studying the RNA expression of SRSF2 mutated UM from TGCA,
we did not observe the same splicing effect as observed in SF3B1 mutated UM. These findings suggest
that SF3B1 mutations compared to mutations in SRSF2 have, despite a similar chromosomal pattern,
a different effect on splicing.
Since we observed SRSF2 mutations in only two patients the clinical impact of this mutation
remains unclear. However, both patients with an SRSF2 mutation in our cohort did not develop
metastasis within 6 and 10 years, neither did the patients from TCGA. In chronic myelomonocytic
leukemia no difference in overall survival was observed, and not in MDS when corrected for age [8,10].
Future studies are needed to evaluate the role of other splicing genes than SF3B1 in UM.
4. Materials and Methods
Patients with an SF3B1-like chromosomal pattern were selected from the Rotterdam Ocular
Melanoma Study group (ROMS) database. These UM patients underwent enucleation or biopsy
of the tumor in the Erasmus Medical Center (Rotterdam, The Netherlands) or The Rotterdam Eye
Hospital (Rotterdam, the Netherlands) between 1993 and 2017. Informed consent from all patients
was obtained before collecting the tumor material. This study was performed according to the tenets
of the Declaration of Helsinki and approved by the local ethics committee (MEC-2009-375, 12th
November 2009).
DNA was isolated from fresh tumor tissue using the QIAamp DNA Mini Kit (Qiagen, Hilden,
Germany) and concentrations measured using the Quant-iT PicoGreen dsDNA Assay Kit (Thermo
Fisher Scientific, Waltham, MA, USA). Two hundred nanograms of DNA input was used for SNP-array
analysis using an Illumina Human SNP array platform (Illumina, San Diego, CA, USA). Copy
number analysis was performed using Nexus Copy Number 8.0 (BioDiscovery, El Segundo, CA, USA).
Moreover, karyotyping was used for CNV analysis when available. Patients were selected from the
cohort described previously [5].
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In general, an SF3B1-like chromosomal pattern is defined as a combination of three structural
variations in SNP array analysis of the tumor (usually this includes either partial gain of chromosome
8q or 9q or partial loss of chromosome 1p or 11q) [5]. In addition, UM with gain of chromosome 6p
or loss of 6q in addition to one or two other anomalies were also included since these anomalies are
also specific for SF3B1 mutated tumors, whereas this is not seen in EIF1AX or BAP1 mutated UM.
Moreover, solely gain of chromosome 6p was only included when the tumor did not harbor an EIF1AX
mutation, because gain of chromosome 6p is only representative for SF3B1 and EIF1AX mutated UM.
The two coding exons of the SRSF2 gene were sequenced using Sanger sequencing with primers
for these regions (pxlence, Dendermonde, Belgium). The mutation hotspots in U2AF1 were sequenced
with primers covering codon 34, 156, and 157. Sanger sequence results were visualized with
SeqScapeSoftware V3.0 (Thermo Fisher Scientific, Waltham, MA, USA) and SeqPilot V4.3.0 (JSI medical
systems GmbH, Ettenheim, Germany).
Mutation analysis of GNAQ, GNA11, SF3B1, BAP1, and EIF1AX was performed previously using
Sanger sequencing and next-generation sequencing using the ION Torrent platform (Life Technologies,
Carlsbad, CA, USA) [5,13]. A BAP1 mutation was defined as a mutation in the BAP1 gene or lack of
nuclear BAP1 expression (performed as described previously [14]).
The UM cohort from the National Insitute of Health TCGA server (n = 80) was used for mutation
analysis of SRSF2 and U2AF1 using Integrative Genomics Viewer (Version 2.3.68 (97) (Broad Institute,
Cambridge, MA, USA). If a mutation in one of these genes was identified, copy number analysis was
performed on the segmented SNP array data using Nexus Copy Number 8.0 (BioDiscovery, El Segundo,
CA, USA).
5. Conclusions
UMs harbor chromosomal aberrations correlated with their mutation status [5]. Mutations in
SF3B1 and SRSF2, genes that are both involved in splicing, occur not only in UM but are described
in MDS and MDS related diseases as well [8–11,15]. However, the mutation type in these genes
are different in both diseases. In UM, SF3B1 is almost exclusively a missense mutation at residue
625 whereas in other diseases residue 700 is mutated [6,11]. In SRSF2, a different type of mutation is
also observed in UM compared to MDS and MDS related diseases, but the same region is involved.
We identified in-frame deletions of SRSF2 in UM in the same genetic region, whereas most mutations
in the same gene in MDS are missense mutations [8]. Therefore, we conclude that there might be a
preference for in-frame deletions in SRSF2 in UM when this gene is involved. We did not observe any
mutation in U2AF1 in our selected cohort, and the incidence of mutations of SRSF2 is low. Although
we have a selected cohort which might influence the incidence, this is in line with previous studies,
in which no or few mutations in these genes are found in UM patients [11,16,17]. The clinical relevance
of CNV pattern and the relation to spliceosome mutations remains unclear. More research is needed to
evaluate the significance of these findings.
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